2 July 2020 - - Canada-based clinical-stage biopharmaceutical company Liminal BioSciences Inc's (NASDAQ: LMNL) (TSX: LMNL) Prometic Plasma Resources subsidiary has commenced the collection of convalescent plasma from donors who have recovered from COVID-19, the company said.

Individuals interested in donating plasma can visit the nearest licensed plasma collection center to their location.

Liminal BioSciences is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel treatments for patients suffering from diseases related to fibrosis, including respiratory, liver and kidney diseases that have high unmet medical need.

Liminal BioSciences said it has a deep understanding of certain biological targets and pathways that have been implicated in the fibrotic process, including fatty acid receptors such as FFAR1, or GPR40, G-protein-coupled receptor 84, or GPR84, and peroxisome proliferator-activated receptors, or PPARs.

In preclinical studies, the company observed that targeting these receptors promoted normal tissue regeneration and scar resolution, including preventing the progression of and reversing established fibrosis.

The company's lead small molecule product candidate, fezagepras (PBI-4050), is expected to enter an additional Phase 1 clinical trial in 2H-2020 to evaluate multiple ascending doses of fezagepras in healthy volunteers, at daily dose exposures higher than those previously evaluated in our completed Phase 1 and Phase 2 clinical trials.

Liminal BioSciences has also leveraged its experience in bioseparation technologies through its subsidiary Prometic Bioproduction Inc. to isolate and purify biopharmaceuticals from human plasma.

Its lead plasma-derived product candidate is Ryplazim (plasminogen), for which the company expects to resubmit a BLA in Q3-2020 with the FDA seeking approval to treat patients with congenital plasminogen deficiency.

Prometic Plasma Resources operates two plasma collection centers in North America managed by a team of qualified professionals with decades of experience in the field of plasma collection.

Its Canadian center located in Winnipeg, Manitoba is licensed by the FDA and Health Canada, and is certified by the European Union and the Plasma Protein Therapeutics Association.

The company's American center located in Amherst, New York is licensed by the State of New York and its' BLA submission is currently under review by the FDA.

Liminal BioSciences has active business operations in Canada, the United Kingdom and the United States.